Raul D. L. L.
- Country
- Spain
- Department
- Servicio de Dermatología
Research Overview
- A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
- Phase 3 Study on the Safety and Efficacy of Upadacitinib Versus Dupilumab in Pediatric Patients Aged 2-12 with Moderate to Severe Atopic Dermatitis
- Evaluation of Baricitinib Pharmacokinetics, Efficacy, and Safety in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 53 of 209 partner sites.
Specializations
Pediatric Dermatology
Specializes in treating skin conditions in children and adolescents, with particular focus on moderate to severe plaque psoriasis and atopic dermatitis in various age groups from 6 months to 18 years.
- Childhood Psoriasis Management
- Pediatric Eczema Treatment
- Netherton Syndrome Research
Investigates innovative therapeutic approaches for rare and common pediatric skin conditions.
Inflammatory Skin Disorders
Focuses on the evaluation of novel therapeutic agents for chronic inflammatory skin conditions, including systemic treatments and combination therapies with topical corticosteroids.
- Advanced Biological Therapies
- Combination Treatment Approaches
- Long-term Disease Management
Explores treatment efficacy in complex dermatological conditions requiring systemic intervention.
Clinical Therapeutics
Evaluates emerging medications including deucravacitinib, lebrikizumab, upadacitinib, and baricitinib for dermatological conditions.
- Novel Drug Development
- Treatment Safety Profiles
- Therapeutic Response Assessment
Conducts research on pharmacological interventions for moderate to severe skin disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.